Sadahisa Ogasawara

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5525853/publications.pdf

Version: 2024-02-01

136	7,949	172386	54882
papers	citations	29 h-index	84 g-index

140	140	140	7782
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver International, 2022, 42, 2055-2066.	1.9	14
2	Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. Journal of Gastroenterology, 2022, 57, 90-98.	2.3	6
3	Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. PLoS ONE, 2022, 17, e0261619.	1.1	4
4	Transition of the tumor microenvironment with clonal evolution of hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, 467-467.	0.8	1
5	Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.. Journal of Clinical Oncology, 2022, 40, TPS495-TPS495.	0.8	1
6	LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2022, 40, TPS494-TPS494.	0.8	2
7	Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, 468-468.	0.8	0
8	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 354-367.	4.2	44
9	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular and Interventional Radiology, 2022, 45, 405-412.	0.9	35
10	Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open, 2022, 12, e059779.	0.8	1
11	Liver cirrhosis is a risk factor for poor prognosis of acute cholangitis caused by choledocholithiasis. Annals of Hepatology, 2022, 27, 100696.	0.6	1
12	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 48-60.	4.2	25
13	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. Liver Cancer, 2022, 11, 329-340.	4.2	5
14	Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience. Journal of Cancer, 2022, 13, 2656-2661.	1.2	6
15	A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. Laboratory Investigation, 2022, 102, 1150-1157.	1.7	4
16	Healthâ€related qualityâ€ofâ€life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTEâ€240. Cancer, 2021, 127, 865-874.	2.0	20
17	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. Journal of Clinical Oncology, 2021, 39, 297-297.	0.8	4
18	A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment. Acta Hepatologica Japonica, 2021, 62, 25-32.	0.0	1

#	Article	IF	Citations
19	Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 268-268.	0.8	10
20	Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. Journal of Cancer, 2021, 12, 2694-2701.	1.2	8
21	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 318-318.	0.8	0
22	Approaching the tumor microenvironment in patients with advanced hepatocellular carcinoma using needle biopsy samples.. Journal of Clinical Oncology, 2021, 39, 334-334.	0.8	0
23	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Scientific Reports, 2021, 11, 5303.	1.6	20
24	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2021, 549, 171-178.	1.0	13
25	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 473-484.	4.2	28
26	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284.	4.2	29
27	REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.. Journal of Clinical Oncology, 2021, 39, TPS4162-TPS4162.	0.8	2
28	Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asiaâ€“Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers, 2021, 13, 2626.	1.7	9
29	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, e16122-e16122.	0.8	0
30	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. Cancers, 2021, 13, 2247.	1.7	8
31	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology, 2021, 39, 4074-4074.	0.8	1
32	Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 4072-4072.	0.8	2
33	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223.	4.2	307
34	Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Case Reports in Oncology, 2021, 14, 1103-1110.	0.3	1
35	Diagnostic value of peroral cholangioscopy in addition to computed tomography for indeterminate biliary strictures. Surgical Endoscopy and Other Interventional Techniques, 2021, , 1.	1.3	1
36	A case of Takotsubo cardiomyopathy after microwave ablation therapy for hepatocellular carcinoma. Acta Hepatologica Japonica, 2021, 62, 548-554.	0.0	0

#	Article	IF	Citations
37	Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2021, 39, 278-278.	0.8	1
38	Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma. Acta Hepatologica Japonica, 2021, 62, 656-662.	0.0	0
39	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open, 2021, 5, 1266-1274.	0.7	9
40	EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Scientific Reports, 2021, 11, 21396.	1.6	17
41	Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. JGH Open, 2021, 5, 273-279.	0.7	4
42	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Investigational New Drugs, 2020, 38, 172-180.	1.2	57
43	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202.	0.8	1,255
44	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 583-595.	4.2	71
45	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer, 2020, 9, 596-612.	4.2	10
46	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 382-396.	4.2	54
47	Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. Japanese Journal of Clinical Oncology, 2020, 50, 1403-1411.	0.6	6
48	Long-term administration of Tolvaptan to patients with decompensated cirrhosis. International Journal of Medical Sciences, 2020, 17, 874-880.	1.1	5
49	Weight-based dosing of lenvatinib for advanced hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 253-254.	0.7	1
50	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. Journal of Clinical Oncology, 2020, 38, 4587-4587.	0.8	2
51	RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. Journal of Clinical Oncology, 2020, 38, 528-528.	0.8	1
52	Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).. Journal of Clinical Oncology, 2020, 38, TPS595-TPS595.	0.8	2
53	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clinical and Molecular Hepatology, 2020, 26, 155-162.	4.5	44
54	Serum creatinine/cystatin C ratio has a potential as a useful surrogate marker for evaluation of muscle mass volume in patients with hepatocellular carcinoma. Journal of Hepatology, 2020, 73, S400.	1.8	1

#	Article	IF	Citations
55	Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer, 2019, 19, 795.	1.1	48
56	Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer, 2019, 19, 1088.	1.1	28
57	FRI-501-Survival among patients with advanced hepatocellular carcinoma in the pre-TKI versus TKI eras. Journal of Hepatology, 2019, 70, e620.	1.8	0
58	FRI-490-The real world practice of systemic therapies in patients with advanced hepatocellular carcinoma in Japan: what has changed since lenvatinib approval?. Journal of Hepatology, 2019, 70, e614-e615.	1.8	0
59	PS-142-Analysis of sorafenib-regorafenib sequential therapy in patients with advanced hepatocellular carcinoma using baseline date of sorafenib. Journal of Hepatology, 2019, 70, e90-e91.	1.8	1
60	Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells. Stem Cells International, 2019, 2019, 1-10.	1.2	5
61	Incidence and hemodynamic feature of risky esophageal varices with lower hepatic venous pressure gradient. International Journal of Medical Sciences, 2019, 16, 1614-1620.	1.1	10
62	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer, 2019, 8, 505-519.	4.2	20
63	Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.. Journal of Clinical Oncology, 2019, 37, 323-323.	0.8	3
64	Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer, 2018, 7, 104-119.	4.2	95
65	Hepatocellular carcinoma after direct-acting antiviral agents: Can liver stiffness kinetics help identify patients at lower risk?. Digestive and Liver Disease, 2018, 50, 580-582.	0.4	0
66	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 424-432.	3.7	216
67	A randomized placeboâ€controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology, 2018, 67, 575-585.	3.6	57
68	Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. Journal of Gastroenterology, 2018, 53, 652-659.	2.3	16
69	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Investigational New Drugs, 2018, 36, 332-339.	1.2	52
70	Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients. PLoS ONE, 2018, 13, e0209352.	1.1	24
71	Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. Hepatology International, 2018, 12, 523-530.	1.9	24
72	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	5.1	1,816

#	Article	IF	Citations
73	Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 2018, 9, 11631-11637.	0.8	10
74	Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. Oncotarget, 2018, 9, 16263-16270.	0.8	5
75	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget, 2018, 9, 21560-21568.	0.8	6
76	Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia. Case Reports in Gastroenterology, 2017, 11, 29-35.	0.3	0
77	Asiaâ€“Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International, 2017, 11, 317-370.	1.9	1,537
78	Presence of nonâ€hypervascular hypointense nodules on Gadoliniumâ€ethoxybenzylâ€diethylenetriamine pentaacetic acidâ€enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 908-915.	1.4	15
79	Hepatocellular carcinoma complicated by acute promyelocytic leukemia: a case report. Acta Hepatologica Japonica, 2017, 58, 176-182.	0.0	0
80	A case of arteriovenous fistula due to a ruptured hepatic aneurysm during sorafenib therapy for hepatocellular carcinoma. Acta Hepatologica Japonica, 2017, 58, 605-610.	0.0	1
81	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. International Journal of Molecular Sciences, 2017, 18, 906.	1.8	28
82	Suspected heparin-induced thrombocytopenia in patients with advanced hepatocellular carcinoma following hepatic arterial infusion chemotherapy. Acta Hepatologica Japonica, 2017, 58, 647-653.	0.0	2
83	Impact of Radiofrequency Ablation-Induced Glissonâ€™s Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. PLoS ONE, 2017, 12, e0170153.	1.1	15
84	Henoch-SchÃ¶nlein Purpura Complicated by Hepatocellular Carcinoma. Internal Medicine, 2017, 56, 3041-3045.	0.3	3
85	Compensating effect of minor portal hypertension on the muscle mass loss-related poor prognosis in cirrhosis. International Journal of Medical Sciences, 2017, 14, 804-810.	1.1	1
86	Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. Oncotarget, 2017, 8, 21315-21326.	0.8	39
87	Clinical outcomes of endoscopic ultrasound-guided ethanol injection for hepatocellular carcinoma in the caudate lobe. Endoscopy International Open, 2016, 04, E1111-E1115.	0.9	12
88	Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. International Journal of Medical Sciences, 2016, 13, 310-315.	1.1	11
89	A case of hepatocellular carcinoma with spontaneous regression of a tumor thrombus invading the main portal trunk. Acta Hepatologica Japonica, 2016, 57, 178-185.	0.0	2
90	Successful treatment of two patients with hepatocellular carcinoma exhibiting severe pancytopenia caused by aplastic anemia. Acta Hepatologica Japonica, 2016, 57, 557-560.	0.0	1

#	Article	IF	Citations
91	Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Investigational New Drugs, 2016, 34, 255-260.	1.2	40
92	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0161303.	1.1	7
93	Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0163119.	1.1	6
94	Dexamethasone for the prevention of transcatheter arterial chemoembolization-induced fever, nausea, vomiting, and anorexia in patients with hepatocellular carcinoma: A randomized, double-blind, placebo-controlled trial.. Journal of Clinical Oncology, 2016, 34, 4071-4071.	0.8	3
95	Tolvaptan treatment for patients with decompensated cirrhosis and advanced hepatocellular carcinoma. Hepatology Research, 2015, 45, E161-2.	1.8	3
96	A case of hepatocellular carcinoma with disappearance of lymph node metastasis after sorafenib administration. Acta Hepatologica Japonica, 2015, 56, 469-476.	0.0	1
97	Two patients with hepatic mucosa-associated lymphoid tissue lymphoma resembling hypervascular hepatocellular carcinoma. Acta Hepatologica Japonica, 2015, 56, 536-539.	0.0	1
98	Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine. Acta Hepatologica Japonica, 2015, 56, 213-216.	0.0	0
99	Successful treatment of three elderly patients aged â‰¥90 years with hepatocellular carcinoma. Acta Hepatologica Japonica, 2015, 56, 628-631.	0.0	1
100	A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. PLoS ONE, 2015, 10, e0125244.	1.1	34
101	Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. International Journal of Cancer, 2015, 136, 289-298.	2.3	87
102	Intensity-Based Assessment of Microbubble-Enhanced Ultrasonography: Phase-Related Diagnostic Ability for Cellular Differentiation of Hepatocellular Carcinoma. Ultrasound in Medicine and Biology, 2015, 41, 3079-3087.	0.7	10
103	Liver function assessment according to the Albuminâ€“Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2015, 33, 1257-1262.	1.2	75
104	Fatal Diaphragmatic Hernia following Radiofrequency Ablation for Hepatocellular Carcinoma: A Case Report and Literature Review. Case Reports in Oncology, 2015, 8, 238-245.	0.3	18
105	Sustained virologic response achieved after curative treatment of hepatitis <scp>C</scp> virusâ€related hepatocellular carcinoma as an independent prognostic factor. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1197-1204.	1.4	36
106	Sorafenib treatment in Childâ€“Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Investigational New Drugs, 2015, 33, 729-739.	1.2	75
107	Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2015, 8, 41-46.	0.4	2
108	Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?. World Journal of Gastroenterology, 2015, 21, 8888.	1.4	3

#	Article	IF	Citations
109	Current management of patients with hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 1913.	0.8	40
110	Biological features and biomarkers in hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 2020.	0.8	12
111	Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. Anticancer Research, 2015, 35, 549-54.	0.5	6
112	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. International Journal of Medical Sciences, 2014, 11, 707-712.	1.1	21
113	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer, 2014, 3, 458-468.	4.2	512
114	Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. Oncology, 2014, 87, 330-341.	0.9	161
115	Partial Splenic Embolization with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Accompanied by Thrombocytopenia. BioMed Research International, 2014, 2014, 1-6.	0.9	4
116	Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. Oncology, 2014, 87, 22-31.	0.9	216
117	Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. PLoS ONE, 2014, 9, e84807.	1.1	70
118	Coronal reformatted CT images contribute to the precise evaluation of the radiofrequency ablative margin for hepatocellular carcinoma. Abdominal Imaging, 2014, 39, 262-268.	2.0	19
119	Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?. International Journal of Clinical Oncology, 2014, 19, 1029-1036.	1.0	4
120	A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2014, 32, 723-728.	1.2	11
121	A phase I/II trial of capecitabine combined with peginterferon Î±-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. Investigational New Drugs, 2014, 32, 762-768.	1.2	5
122	Successful Interventional Treatment for Arterioportal Fistula Caused by Radiofrequency Ablation for Hepatocellular Carcinoma. Case Reports in Oncology, 2014, 7, 833-839.	0.3	10
123	Intracranial Metastasis in a Patient with Hepatocellular Carcinoma and Gastric Cancer. Case Reports in Oncology, 2014, 7, 199-203.	0.3	5
124	A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients.. Journal of Clinical Oncology, 2014, 32, 346-346.	0.8	0
125	Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma. Anticancer Research, 2014, 34, 4231-7.	0.5	21
126	Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. Hepatology International, 2013, 7, 703-713.	1.9	7

#	Article	IF	Citations
127	Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan. Hepatology International, 2013, 7, 1030-1039.	1.9	6
128	Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magnetic Resonance Imaging, 2013, 31, 748-754.	1.0	34
129	Simultaneous Resection of Disseminated Hepatocellular Carcinoma and Colon Cancer. Case Reports in Gastroenterology, 2013, 7, 37-43.	0.3	1
130	Successful Resection of Intracranial Metastasis of Hepatocellular Carcinoma. Case Reports in Gastroenterology, 2013, 7, 182-187.	0.3	3
131	Successful Non-surgical Treatment of Ruptured Pyogenic Liver Abscess. Internal Medicine, 2013, 52, 2619-2622.	0.3	6
132	Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma Cells. PLoS ONE, 2013, 8, e70010.	1.1	66
133	Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma. Anticancer Research, 2013, 33, 5603-9.	0.5	3
134	Hepatic Sarcoidosis with an Increased Serum Level of Immunoglobulin G4. Internal Medicine, 2012, 51, 3095-3098.	0.3	6
135	Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatology International, 2011, 5, 850-856.	1.9	40
136	Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis. International Journal of Clinical Oncology, 0, , .	1.0	1